73
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      Acute myocardial infarction: a comparison of short-term survival in national outcome registries in Sweden and the UK

      research-article
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Summary

          Background

          International research for acute myocardial infarction lacks comparisons of whole health systems. We assessed time trends for care and outcomes in Sweden and the UK.

          Methods

          We used data from national registries on consecutive patients registered between 2004 and 2010 in all hospitals providing care for acute coronary syndrome in Sweden and the UK. The primary outcome was all-cause mortality 30 days after admission. We compared effectiveness of treatment by indirect casemix standardisation. This study is registered with ClinicalTrials.gov, number NCT01359033.

          Findings

          We assessed data for 119 786 patients in Sweden and 391 077 in the UK. 30-day mortality was 7·6% (95% CI 7·4–7·7) in Sweden and 10·5% (10·4–10·6) in the UK. Mortality was higher in the UK in clinically relevant subgroups defined by troponin concentration, ST-segment elevation, age, sex, heart rate, systolic blood pressure, diabetes mellitus status, and smoking status. In Sweden, compared with the UK, there was earlier and more extensive uptake of primary percutaneous coronary intervention (59% vs 22%) and more frequent use of β blockers at discharge (89% vs 78%). After casemix standardisation the 30-day mortality ratio for UK versus Sweden was 1·37 (95% CI 1·30–1·45), which corresponds to 11 263 (95% CI 9620–12 827) excess deaths, but did decline over time (from 1·47, 95% CI 1·38–1·58 in 2004 to 1·20, 1·12–1·29 in 2010; p=0·01).

          Interpretation

          We found clinically important differences between countries in acute myocardial infarction care and outcomes. International comparisons research might help to improve health systems and prevent deaths.

          Funding

          Seventh Framework Programme for Research, National Institute for Health Research, Wellcome Trust (UK), Swedish Association of Local Authorities and Regions, Swedish Heart-Lung Foundation.

          Related collections

          Most cited references39

          • Record: found
          • Abstract: found
          • Article: not found

          Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials.

          Many trials have been done to compare primary percutaneous transluminal coronary angioplasty (PTCA) with thrombolytic therapy for acute ST-segment elevation myocardial infarction (AMI). Our aim was to look at the combined results of these trials and to ascertain which reperfusion therapy is most effective. We did a search of published work and identified 23 trials, which together randomly assigned 7739 thrombolytic-eligible patients with ST-segment elevation AMI to primary PTCA (n=3872) or thrombolytic therapy (n=3867). Streptokinase was used in eight trials (n=1837), and fibrin-specific agents in 15 (n=5902). Most patients who received thrombolytic therapy (76%, n=2939) received a fibrin-specific agent. Stents were used in 12 trials, and platelet glycoprotein IIb/IIIa inhibitors were used in eight. We identified short-term and long-term clinical outcomes of death, non-fatal reinfarction, and stroke, and did subgroup analyses to assess the effect of type of thrombolytic agent used and the strategy of emergent hospital transfer for primary PTCA. All analyses were done with and without inclusion of the SHOCK trial data. Primary PTCA was better than thrombolytic therapy at reducing overall short-term death (7% [n=270] vs 9% [360]; p=0.0002), death excluding the SHOCK trial data (5% [199] vs 7% [276]; p=0.0003), non-fatal reinfarction (3% [80] vs 7% [222]; p<0.0001), stroke (1% [30] vs 2% [64]; p=0.0004), and the combined endpoint of death, non-fatal reinfarction, and stroke (8% [253] vs 14% [442]; p<0.0001). The results seen with primary PTCA remained better than those seen with thrombolytic therapy during long-term follow-up, and were independent of both the type of thrombolytic agent used, and whether or not the patient was transferred for primary PTCA. Primary PTCA is more effective than thrombolytic therapy for the treatment of ST-segment elevation AMI.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Universal definition of myocardial infarction.

              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update) a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.

                Bookmark

                Author and article information

                Contributors
                Journal
                Lancet
                Lancet
                Lancet
                Lancet Publishing Group
                0140-6736
                1474-547X
                12 April 2014
                12 April 2014
                : 383
                : 9925
                : 1305-1312
                Affiliations
                [a ]Farr Institute of Health Informatics Research at UCL Partners, University College London, London, UK
                [b ]National Institute for Clinical Outcomes Research, University College London, London, UK
                [c ]Centre for Cardiovascular Prevention and Outcomes, University College London, London, UK
                [d ]Uppsala Clinical Research Centre, Uppsala University, Uppsala, Sweden
                [e ]Department of Medical Sciences, Cardiology, Uppsala University, Uppsala, Sweden
                [f ]Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
                [g ]Department of Cardiothoracic Surgery, Sahlgrenska University Hospital, Gothenburg, Sweden
                [h ]Division of Health and Social Care Research, King's College London, London, UK
                [i ]National Institute of Health Research Comprehensive Biomedical Research Centre, Guy's & St Thomas' NHS Foundation Trust and King's College London, London, UK
                [j ]Institute for Clinical Epidemiology and Biometry and Comprehensive Heart Failure Centre, University of Würzburg, Würzburg, Germany
                [k ]National Institute for Health Research, Biomedical Research Unit, Bart's Health London, London, UK
                [l ]Department of Medicine, Huddinge, Section of Cardiology, Karolinska Institute, Stockholm, Sweden
                Author notes
                [* ]Correspondence to: Dr Tomas Jernberg, Department of Cardiology, Karolinska University Hospital, Karolinska Institute, Huddinge 141 86, Stockholm, Sweden tomas.jernberg@ 123456karolinska.se
                [** ]Prof Harry Hemingway, Farr Institute of Health Informatics Research at UCL Partners, University College London, 222 Euston Road, London NW1 2DA, UK h.hemingway@ 123456ucl.ac.uk
                Article
                S0140-6736(13)62070-X
                10.1016/S0140-6736(13)62070-X
                4255068
                24461715
                da730373-bed5-43dd-a78b-a5ee2de7a196
                © 2014 Chung et al. Open Access article distributed under the terms of CC BY

                This document may be redistributed and reused, subject to certain conditions.

                History
                Categories
                Articles

                Medicine
                Medicine

                Comments

                Comment on this article